Abstract:Broad-scale untargeted biochemical phenotyping is a technology that supplements widely accepted assays, such as organic acid, amino acid, and acylcarnitine analyses typically utilized for the diagnosis of inborn errors of metabolism. In this study, we investigate the analyte changes associated with 4-aminobutyrate aminotransferase (ABAT, GABA transaminase) deficiency and treatments that affect GABA metabolism. GABA-transaminase deficiency is a rare neurodevelopmental and neurometabolic disorder caused by mutations in ABAT and resulting in accumulation of GABA in the cerebrospinal fluid (CSF). For that reason, measurement of GABA in CSF is currently the primary approach to diagnosis. GABA-transaminase deficiency results in severe developmental delay with intellectual disability, seizures, and movement disorder, and is often associated with death in childhood. Using an untargeted metabolomics platform, we analyzed EDTA plasma, urine, and CSF specimens from four individuals with GABA-transaminase deficiency to identify biomarkers by comparing the biochemical profile of individual patient samples to a pediatric-centric population cohort. Metabolomic analyses of over 1,000 clinical plasma samples revealed a rich source of biochemical information. Three out of four patients showed significantly elevated levels of the molecule 2-pyrrolidinone (Z-score ≥2) in plasma, and whole exome sequencing revealed variants of uncertain significance in ABAT. Additionally, these same patients also had elevated levels of succinimide in plasma, urine, and CSF and/or homocarnosine in urine and CSF. In the analysis of clinical EDTA plasma samples, the levels of succinimide and 2-pyrrolidinone showed a high level of correlation (R = 0.73), indicating impairment in GABA metabolism and further supporting the association with GABA-transaminase deficiency and the pathogenicity of the ABAT variants. Further analysis of metabolomic data across our patient population revealed the association of elevated levels of 2-pyrrolidinone with administration of vigabatrin, a commonly used anti-seizure medication and a known inhibitor of GABA-transaminase. These data indicate that anti-seizure medications may alter the biochemical and metabolomic data, potentially impacting the interpretation and diagnosis for the patient. Further, these data demonstrate the power of combining broad scale genotyping and phenotyping technologies to diagnose inherited neurometabolic disorders and support the use of metabolic phenotyping of plasma to screen for GABA-transaminase deficiency.

Comprehensive metabolomics analysis reveals novel biomarkers and pathways in falsely suspected glutaric aciduria Type-1 newborns

[Genetic Analysis of Newborns with Abnormal Metabolism of 3-Hydroxyisovalerylcarnitine].

[Screening for Newborn Organic Aciduria in Zhejiang Province:Prevalence, Outcome and Follow-Up].

Diagnosis of glutaric aciduria type 1 by measuring 3-hydroxyglutaric acid in dried urine spots by liquid chromatography tandem mass spectrometry

Prenatal Diagnosis of Glutaric Acidemia I Based on Amniotic Fluid Samples in 42 Families Using Genetic and Biochemical Approaches

Analysis of Clinical Features and the Results of Mass Spectrometry with Glutaric Acidemia Type I

Two inborn errors of metabolism in a newborn: glutaric aciduria type I combined with isobutyrylglycinuria

[Mass Spectrometry Combined with Gene Analysis for Prenatal Diagnosis of Glutaric Acidemia Type Ⅰ].

Biochemical and Molecular Features of Chinese Patients with Glutaric Acidemia Type 1 from Fujian Province, Southeastern China

Evaluation of the Clinical, Biochemical, Neurological, and Genetic Presentations of Glutaric Aciduria Type 1 in Patients from China

AB054. Experiences During Newborn Screening for Glutaric Aciduria Type 1: Diagnosis, Treatment, Genotype, Phenotype and Outcomes

Clinical and Mutational Spectra of 23 Chinese Patients with Glutaric Aciduria Type 1.

2-Pyrrolidinone and Succinimide As Clinical Screening Biomarkers for GABA-Transaminase Deficiency: Anti-seizure Medications Impact Accurate Diagnosis.

The First Pediatric Case of Glucagon Receptor Defect Due to Biallelic Mutations in GCGR is Identified by Newborn Screening of Elevated Arginine

[Expert Consensus for the Diagnosis and Treatment of Glutaricacidemia Type 1].

[Analysis of disease spectrum for abnormal 3-hydroxyisovalerylcarnitine metabolism identified through newborn screening and clinical diagnosis].

Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review

Metabonomics Reveals Metabolite Changes in Biliary Atresia Infants

Clinical and Molecular Investigation in Chinese Patients with Glutaric Aciduria Type I

[Clinical and Genetic Analysis of an Infant with 3-Methylglutaconic Aciduria Type VII].

Exploratory Untargeted Metabolomics of Dried Blood Spot Samples from Newborns with Maple Syrup Urine Disease